Literature DB >> 23195020

Drug interaction between tacrolimus and ertapenem in renal transplantation recipients.

F Bora1, I Aliosmanoglu, H Kocak, A Dinckan, H B Uslu, F Gunseren, G Suleymanlar.   

Abstract

To show drug interactions between tacrolimus and ertapenem, we retrospectively evaluated 13 renal transplant recipients who had been treated with ertapenem for urinary tract infections during prescription of a constant dose. The mean dose of tacrolimus to achieve desired therapeutic concentrations decreased significantly after beginning ertapenem. The decrease from 0.079 mg/kg to 0.043 mg/kg occurred 2 days after initiation of ertapenem (P < .005). These results suggest that ertapenem, which is not metabolized through the cytochrome (CYP) P450 3A metabolic pathway, interacts with tacrolimus by an unknown mechanism. This report recommends tacrolimus concentration monitoring and dose reductions when the two drugs are administered in combination.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23195020     DOI: 10.1016/j.transproceed.2012.08.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution.

Authors:  Ashraf G Madian; Arun Panigrahi; Minoli A Perera; Navin Pinto
Journal:  BMC Pharmacol Toxicol       Date:  2014-12-03       Impact factor: 2.483

2.  Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation.

Authors:  Gemma Sanclemente; Marta Bodro; Carlos Cervera; Laura Linares; Frederic Cofán; Francesc Marco; Jordi Bosch; Federico Oppenheimer; Fritz Dieckmann; Asunción Moreno
Journal:  BMC Nephrol       Date:  2019-07-22       Impact factor: 2.388

Review 3.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.